Mucopolysaccharidosis I - 101 Studies Found
Completed |
: A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease :
|
Recruiting |
: A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants :
|
Terminated |
: Clinical Trial of Growth Hormone in MPS I, II, and VI :
: Drug: Somatropin (DNA origin) The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divid |
Completed |
: A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old :
|
Completed |
: Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I :
|
Recruiting |
: Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI :
: 2015-05-05 : |
Terminated |
: Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I :
: Drug: laronidase 0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per mont |
Completed |
: A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I :
: Drug: laronidase 1.74 mg intrathecally every 1-3 months for 1 year |